Supreme Court of the United States · Official docket →
Merck & Co., Inc., et al. v. Gilead Sciences, Inc.
Paid petition · United States Court of Appeals for the Federal Circuit, No. 2016-2302, 2016-2615 · judgment April 25, 2018
Certiorari denied · January 7, 2019
Pre-decision estimate: 4% cert probability
Before the decision, roughly the 4.1% base rate. The model weighted this up for counsel with five or more prior petitions here, a dissent in the court below (flagged in the petition), and a Federal Circuit decision below, and down for a business respondent.
Question presented
MICHELLE J. PARTHUM MOLOLAMKEN LLP 300 North LaSalle Street Chicago, IL 60654 (312) 450-6700 mparthum@mololamken.com
Counsel of record
For petitioner
Jeffrey Alan Lamken
MoloLamken LLP
For respondent
E. Joshua Rosenkranz
Orrick, Herrington & Sutcliffe LLP
Proceedings
- Jan 07 2019Petition DENIED.
- Nov 28 2018DISTRIBUTED for Conference of 1/4/2019.
- Nov 27 2018Reply of petitioners Merck & Co., Inc., et al. filed.
- Nov 14 2018Brief of respondent Gilead Sciences, Inc. in opposition filed.
- Oct 24 2018Brief amicus curiae of Samuel L. Bray filed.
- Oct 24 2018Brief amicus curiae of Celgene Corporation filed.
- Oct 15 2018Motion to extend the time to file a response is granted and the time is extended to and including November 23, 2018.
- Oct 11 2018Motion to extend the time to file a response from October 24, 2018 to November 23, 2018, submitted to The Clerk.
- Sep 21 2018Petition for a writ of certiorari filed. (Response due October 24, 2018)
- Jul 16 2018Application (18A51) granted by The Chief Justice extending the time to file until September 21, 2018.
- Jul 12 2018Application (18A51) to extend the time to file a petition for a writ of certiorari from July 24, 2018 to September 21, 2018, submitted to The Chief Justice.